💥💥Louisville, KY Psychedelic Psychiatry Lunch and Learn this Friday 3/22 Please attend this free event featuring three certified providers of Psychedelic Assisted Therapy in the Louisville area. We will not be serving psychedelics or lunch, but light refreshments will be available. 😁 If you are like us, you like to get to know other clinicians before making and accepting referrals. Given the novelty and excitement surrounding the “psychedelic renaissance” happening in mental health and the broader cultural context, it’s important to have reliable resources from trained and experienced professionals. Please come prepared to both share any expertise you have, as well as to learn with your colleagues. "It does not seem to be an exaggeration to say that psychedelics, used responsibly and with proper caution, would be for psychiatry what the microscope is for biology and medicine or the telescope is for astronomy. These tools make it possible to study important processes that under normal circumstances are not available for direct observation." - Dr. Stan Grof, MD Location: 7608 West Highway 146, Pewee Valley, KY 40056 Date: Friday 3/22/2024 Time: 12-2pm RSVP via email to jim@inner-view.us or text 502-724-1770 12-1pm: Presentation on the most current evidence-based practices in the psychedelic psychotherapy landscape including the risks, benefits, and alternatives regarding ketamine, MDMA, and psilocybin-assisted therapies. 1-2pm: Q&A/Open round table discussion with all attendees https://lnkd.in/gS8bgWwy
Doc Askins’ Post
More Relevant Posts
-
In collaboration with STALICLA, clinical Phase 1 trials are being led by Drs. Suchitra Krishnan-sarin, John Krystal and Stephanie O'Malley from the Department of Psychiatry of the Yale University School of Medicine under a center grant from the National Institute on Alcohol Abuse and Alcoholism. One of the studies aims to conduct a comprehensive examination of the influence of STP7 (Mavoglurant) on alcohol drinking behaviors among heavy drinkers. The study will also assess the potential of mavoglurant as a treatment candidate to benefit patients affected by Alcohol Use Disorder. Under the agreement, STALICLA will provide STP7 (Mavoglurant) to the principal investigator of the NIAAA center, Dr. John Krystal. Dr. Krystal is a leading expert in the areas of substance use disorders, post-traumatic stress disorder, schizophrenia, and depression, and is currently Chair of the Department of Psychiatry of the Yale University School of Medicine. #Stalicla #Neurology #Innovation #Biotechnology #CNS #precisionmedicine #neuropsychiatry
To view or add a comment, sign in
-
Next lecture on Philosophy & Psychiatry Seminar (Institut društvenih nauka - Institute of Social Sciences): “The Drug Worked for Me” … But Did It? Jacob Stegenga (with Hamed Tabatabaei Ghomi) In his presentation, Dr Jacob Stegenga will question whether inferences from patients' first-person experiences about the effectiveness of their prescribed psychiatric drugs are reliable. Join us on April 18, 11.00 CET! 🙂 https://lnkd.in/dXymfvE5
To view or add a comment, sign in
-
How TMS Therapy Works ? 🧠 Discover the Science Behind TMS Therapy! 🧠 Curious about how TMS Therapy works? This innovative treatment uses targeted magnetic pulses to stimulate specific areas of the brain involved in mood regulation. It’s particularly effective for those battling Treatment-Resistant Depression (TDR). A recent meta-analysis in the Brain Stimulation journal found that TMS Therapy significantly reduces depressive symptoms in patients who haven’t found relief with traditional methods. By directly targeting the brain’s neural circuits, TMS Therapy can help reset and normalize brain function, leading to improved mood and well-being. Experience the revolutionary impact of TMS Therapy at Advanced Psychiatry of Elgin. Our team is here to guide you through every step of this transformative journey. #TMSTherapy #BrainHealth #MentalWellness #AdvancedPsychiatryElgin WE ARE HERE FOR YOU! 🌿 📲 847.783.0307 https://lnkd.in/eyeuXEj
To view or add a comment, sign in
-
🌍 A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. 🧠 With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters
To view or add a comment, sign in
-
🌍 A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. 🧠 With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters
To view or add a comment, sign in
-
🌍 A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. 🧠 With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters
To view or add a comment, sign in
-
NeuroTech | Healthcare AI | Digital Health | Digital Biomarker | EEG | Signal Processing | Deep Learning/Machine Learning | Precision Medicine | Clinical Research
🌍 A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. 🧠 With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters
To view or add a comment, sign in
-
[For Academy Students: RSVP for a Live Session tomorrow] Comparing Antipsychotics: with Pneumonia Risk [Understanding the Anticholinergic Burden] On June 26, 2024: JAMA Psychiatry published this cohort study of people with schizophrenia to assess the association of antipsychotics with pneumonia. In this upcoming Live video, Dr. Harvinder Singh will summarize this findings to answer the following questions: (1) Mechanism: What is the likely mechanism(s) behind antipsychotics induced pneumonia risk? (2) Risk Factors: Which patients with schizophrenia are more at risk? (3) Antipsychotics Dose: Can dose of antipsychotics impact the pneumonia risk? (4) Risk for Antipsychotics Monotherapy vs Polytherapy. (5) Comparing Antipsychotics: Which antipsychotics have HIGHEST & LOWEST risk of Pneumonia? RSVP here: https://lnkd.in/gChBVMg6
To view or add a comment, sign in
-
How TMS Therapy Works ? 🧠 Discover the Science Behind TMS Therapy! 🧠 Curious about how TMS Therapy works? This innovative treatment uses targeted magnetic pulses to stimulate specific areas of the brain involved in mood regulation. It’s particularly effective for those battling Treatment-Resistant Depression (TDR). A recent meta-analysis in the Brain Stimulation journal found that TMS Therapy significantly reduces depressive symptoms in patients who haven’t found relief with traditional methods. By directly targeting the brain’s neural circuits, TMS Therapy can help reset and normalize brain function, leading to improved mood and well-being. Experience the revolutionary impact of TMS Therapy at Advanced Psychiatry of Elgin. Our team is here to guide you through every step of this transformative journey. #TMSTherapy #BrainHealth #MentalWellness #AdvancedPsychiatryElgin WE ARE HERE FOR YOU! 🌿 📲 847.783.0307 https://lnkd.in/gYX3qje
To view or add a comment, sign in
Art Therapy Program Director at University of Louisville
7moMy fridays are pretty full. I need more advanced notice!!